Simplified plasma essential amino acid-based profiling provides metabolic information and prognostic value additive to traditional risk factors in heart failure

被引:0
作者
Chao-Hung Wang
Mei-Ling Cheng
Min-Hui Liu
机构
[1] Chang Gung Memorial Hospital,Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine
[2] Chang Gung University College of Medicine,Metabolomics Core Laboratory, Healthy Aging Research Center
[3] Chang Gung University,Department and Graduate Institute of Biomedical Sciences, College of Medicine
[4] Chang Gung University,Clinical Metabolomics Core Laboratory
[5] Linkou Chang Gung Memorial Hospital,Department of Nursing
[6] National Yang-Ming University,undefined
来源
Amino Acids | 2018年 / 50卷
关键词
Heart failure; Metabolomics; Amino acid; Prognosis; B-type natriuretic peptide;
D O I
暂无
中图分类号
学科分类号
摘要
In heart failure (HF), metabolic disturbances represent functional perturbations in peripheral tissues and also predict patient outcomes. This study developed a simplified essential amino acid-based profile and tested whether it could improve prognostication. Plasma essential amino acids and lipidomics were measured on 1084 participants. The initial cohort included 94 normal controls and 599 patients hospitalized due to acute/decompensated HF. The validation cohort included 391 HF patients. Patients were followed for composite events (death/HF related re-hospitalization) and were categorized into three groups: high risk type 1 (leucine ≥145 μM and phenylalanine ≥ 88.9 μM), high risk type 2 (leucine < 81.2 μM), and low risk (other). Types 1 and 2 were associated with higher event rates [hazard ratio (95% confidence intervals) = 1.88 (1.27–2.79) and 7.71 (4.97–11.9), respectively, p < 0.001]. Compared to the low-risk group, both types of high-risk patients were older and had lower blood pressure and estimated glomerular filtration rates, but higher B-type natriuretic peptides (BNP). In addition, type 1 was associated with more incompletely metabolized lipids in the blood; type 2 patients had lower body mass indexes, rates of using guideline-based medications, and levels of cholesterol, hemoglobin, and albumin. The prognostic value of types 1 and 2 remained significant after adjusting for age, BNP and other risk factors. The value of using high-risk types for prognosis was confirmed in the validation cohort. In conclusion, simplified essential amino acid-based profiling identified two high-risk populations and provided metabolic information and prognostic value additive to traditional risk factors.
引用
收藏
页码:1739 / 1748
页数:9
相关论文
共 45 条
[1]  
Ahmad T(2016)Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support J Am Coll Cardiol 67 291-299
[2]  
Kelly JP(2012)Preserved muscle protein metabolism in obese patients with chronic heart failure Int J Cardiol 160 102-108
[3]  
Aquilani R(2015)Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics J Am Coll Cardiol 65 1509-1520
[4]  
La Rovere MT(2016)Natriuretic peptide-guided management in heart failure J Cardiovasc Med 17 556-568
[5]  
Cheng ML(2007)Simple and rapid quantitative high-performance liquid chromatographic analysis of plasma amino acids J Chromatogr B Analyt Technol Biomed Life Sci 852 646-649
[6]  
Wang CH(2011)Metabolomics as a tool for cardiac research Nat Rev Cardiol 8 630-643
[7]  
Chioncel O(2015)Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure PLoS One 10 e0117325-131
[8]  
Collins SP(2016)Metabolic dysfunction in heart failure: diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling Curr Heart Fail Rep 13 119-211
[9]  
Frank MP(2013)Formal cardiac rehabilitation and exercise training programs in heart failure: evidence for substantial clinical benefits J Cardiopulm Rehabil Prev 33 209-E1112
[10]  
Powers RW(2002)Human protein metabolism: its measurement and regulation Am J Physiol Endocrinol Metab 283 E1105-1084